Business

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof). H.C. Wainwright & Co. acted as the exclusive placement agent for the offe

articleKala Bio, Inc.December 5, 20253/company/kala-pharmaceuticals-inc/news/kala-bio-announces-closing-10-193600187
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

About this update from Kala Bio, Inc.

[{"type":"image","alt":"KALA BIO, Inc.","displaySize":"","headline":null,"caption":"KALA BIO, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":210,"url":"https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/poFKt69Bd.mweg6BAiQGYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46","width":300,"height":210}},"lazy":false},{"type":"text","content":"ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof).","length":426,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.","length":82,"tagName":"p"},{"type":"text","content":"The aggregate gross proceeds to the Company from the offering were approximately $10 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering to repay certain of its indebtedness and for general corporate purposes.","length":332,"tagName":"p"},{"type":"text","content":"The securities described above were offered pursuant to a “shelf” registration statement (File No. 333-270263) filed with the Securities and Exchange Commission (“SEC”) on March 3, 2023 and declared effective on May 11, 2023. The offering was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered was filed with the SEC and is available at the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@...

More updates from Kala Bio, Inc.

Securities and Exchange CommissionKALAprospectus supplementThe Companyregistration statementsecurities lawsForward-Looking Statements